VOI - Voice of Indonesia | RRI - Radio Republik Indonesia

PT Bio Farma revealed that as many as 837 clinical trial volunteers III of the COVID-19 vaccine from Sinovac China entered the efficacy monitoring period.

"The latest data shows that as of October 23, 2020, 837 volunteers entered the efficacy monitoring period," said Bio Farma's Head of Corporate Communication Iwan Setiawan when contacted by Antara in Jakarta, Tuesday.

In addition, Iwan also added that 1,620 volunteers had received the first injection and 1,341 volunteers received the second injection.

"Currently, the third clinical trial of the COVID-19 vaccine is still going according to plan," he said.

The Head of Corporate Communication of Bio Farma also said that some time ago a team from the POM Agency carried out inspections of two Puskesmas as a place for conducting clinical trials of the Covid-19 vaccine.

Previously, President Joko Widodo hoped that the COVID-19 vaccine goes through a correct clinical trial so that its safety and effectiveness could be ascertained.

The president said the government did not want any problems affecting the vaccine recipient community. The President asked his staff not to hurry and continue to promote scientific principles for the COVID-19 vaccine.

All scientific procedures regarding vaccines and vaccinations must be passed precisely, without missing anything.

At present, all parties, be it the public, researchers, academics, and others are monitoring the process of procuring and implementing the COVID-19 vaccine in Indonesia.

Therefore, all stages of procurement and implementation of the COVID-19 vaccine must comply with scientific criteria. (Antaranews)